News
Company News: Curetis and Laboratorios LETI Sign Exclusive Distribution Agreement for Unyvero™ in Spain and Portugal
– Five-year agreement based on extensive health economic assessment –
Curetis AG today announced that the company has closed an exclusive distribution agreement in Spain and Portugal with Laboratorios LETI, which includes all existing and future Unyvero™ instruments and consumables. LETI is a biopharmaceutical company based in Tres Cantos, near Madrid, Spain. Its diagnostics business unit distributes and markets a broad portfolio of in vitro diagnostics (IVD) and research products, among other offerings.
The agreement, effective January 1, 2014, was finalized following positive market feedback and favorable outcome of a joint, extensive health economic assessment which included four major hospitals in Spain and Portugal. The commercial launch of Unyvero™ in this region is expected in the first quarter of 2014.
For the implementation, Curetis will provide Unyvero training, marketing materials and supporting health economic research. LETI will manage all marketing and sales activities as well as storage and logistics support. The partners are targeting a market share of more than 50 percent of relevant hospitals and ICU units in the region within the next five years.
Company News: Anergis Appoints Dr. Dino Dina to its Board of Directors
– Company appoints seasoned US vaccine and biotech executive –
Anergis, a company focusing on proprietary allergy vaccines, today announced the appointment of Dino Dina, MD, to its Board of Directors. Dr. Dina brings extensive expertise in the research and development of vaccines for allergy, cancer and infectious diseases as well as in building successful US biopharmaceutical companies.
From 1998 to 2013, Dr. Dina served as Chief Executive Officer of Dynavax Technologies Corporation and has been a member of Dynavax´ Board of Directors since 1997. During his tenure, he secured extensive financing through corporate alliances (UCB, Sanofi, AstraZeneca, GSK, Merck), private financings, an initial public offering (2004), and a series of public equity financings. Prior to joining Dynavax, Dr. Dina held a series of positions with increasing responsibility at Chiron Corporation, where he ultimately served as President of Chiron Vaccines. Under Dr. Dina’s direction, Chiron Vaccines received the first-ever approval of an adjuvanted influenza vaccine in Italy, successfully completed development of the first genetically engineered pertussis vaccine, and conducted clinical trials for vaccines to prevent HIV, herpes simplex type II, cytomegalovirus, and hepatitis B infections.
Company News: Curetis Receives Clearance for Unyvero™ System and Pneumonia Application in Russia and Serbia
– First Unyvero™ Systems installed for clinical evaluation
– Presentation at 23rd National Congress on Lung Diseases in Kazan
Curetis AG today announced that its Unyvero™ System and its Unyvero™ P50 Application have been registered and cleared by the Russian and Serbian Ministry of Health, respectively.
The first Unyvero™ System has already been installed for approbation at the Central Clinical Hospital of the Presidential Administration of the Russian Federation in Moscow and another will be tested at one of the major hospitals in St. Petersburg.
Curetis´ distribution partner, BioLine LLC, is currently presenting the Unyvero™ System at major clinical and scientific events in Russia. Likewise, Curetis’ distribution partner Ako med d.o.o. is demonstrating the Unyvero™ System at major hospitals in Serbia, Bosnia Hercegovina, Croatia and Slovenia.